Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma

NCT07488624 — Completed, 414 participants, Sichuan University

ClinicalTrials Daily · Areas · Conditions · Drugs · Sponsors ·

Development and Internal Validation of a Clinicopathologic Prognostic Model for Overall Survival in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoimmunotherapy and Esophagectomy: A Multicenter Retrospective Cohort Study

Registry	NCT07488624
Status	Completed
Study type	Observational
Enrollment	414 (Actual)
Sponsor	Sichuan University (Other)
Conditions	Esophageal Squamous Cell Carcinoma
Dates	start 2026-03-01, primary completion 2026-06-01, completion 2026-06-01, first posted 2026-03-23, last updated 2026-08-13
Locations	3 sites in China

-Summary

The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy followed by esophagectomy.

Researchers will review existing clinical, pathologic, and follow-up data from 414 patients treated at three medical centers between 2019 and 2025. The study will assess whether routinely available clinicopathologic factors can provide prognostic information beyond postoperative pathologic staging.

Expand all sections · Collapse all

+Arms and interventions

Arm	Type	Interventions	Description
ESCC Cohort After Neoadjuvant Chemoimmunotherapy and Esophagectomy			This cohort includes patients aged 18-80 years with histologically confirmed esophageal squamous cell carcinoma who received at least one cycle of neoadjuvant chemoimmunotherapy followed by esophagectomy. Patients were treated at three participating medical centers between 2019 and 2025.

+Outcome measures

Primary outcomes

Overall Survival (OS) [From the date of esophagectomy to death or last follow-up, up to 73 months.]: Overall survival is defined as the interval from the date of esophagectomy to death from any cause. Participants alive at last contact are censored on the date of last follow-up.

+Eligibility

Sex: All, ages: 18 Years to 80 Years

Inclusion Criteria:

Age 18 to 80 years Histologically confirmed esophageal squamous cell carcinoma Received at least 1 cycle of neoadjuvant chemoimmunotherapy before surgery Underwent subsequent esophagectomy

Exclusion Criteria:

History of other malignancies Preoperative antitumor therapy other than neoadjuvant chemoimmunotherapy Incomplete clinicopathologic or follow-up data

+Locations (3)

Facility	City	Country
West China Hospital, Sichuan University	Chengdu, Sichuan	China
Mianzhu People's Hospital (West China Mianzhu Hospital, Sichuan University)	Mianzhu, Sichuan	China
Suining Central Hospital	Suining, Sichuan	China